Leif W. Ellisen

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells

  Proceedings of the National Academy of Sciences · 2026-06-17

• Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

  The Lancet Oncology · 2026-04-27

• Abstract LB194: SIRT5 induces a metabolic switch to fuel nucleotide pools and chemoresistance in triple-negative breast cancer

  Cancer Research · 2026-04-17

• A SIRT5-induced metabolic switch underlies chemoresistance and ATR checkpoint dependence in triple-negative breast cancer

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-04-09

• Sensitive detection of somatic mutations in GC-rich cancer gene promoters

  NAR Cancer · 2026-04-08

• TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer

  Journal for ImmunoTherapy of Cancer · 2026-04-01 · 2 citations

• MassIVE MSV000101354 - A SIRT5-induced metabolic switch underlies chemoresistance and ATR checkpoint dependence in triple-negative breast cancer

  UC San Diego · 2026-01-01

• A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer 2059

  The Journal of Immunology · 2025-11-01

• 665 TROP2 remodeling of the immune microenvironment in triple negative breast cancer

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Selection biases in the systematic collection of breast biobank specimens

  npj Breast Cancer · 2025-08-01 · 1 citations

• A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

  EBioMedicine · 2025-06-27 · 7 citations

• Abstract P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis

  Clinical Cancer Research · 2025-06-13

• Abstract P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy & a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial

  Clinical Cancer Research · 2025-06-13

• Abstract P3-04-06: Genomic and transcriptomic profiling of BRCA mutation carrier tissues reveals the landscape of early pathogenesis of BRCA1/2-associated breast cancer

  Clinical Cancer Research · 2025-06-13

• Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

  Breast Cancer Research and Treatment · 2025-05-29 · 1 citations

• Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.

  Journal of Clinical Oncology · 2025-05-28 · 11 citations

• A retrospective analysis of metaplastic triple negative breast cancer response to sacituzumab govitecan and candidacy for targeted therapy.

  Journal of Clinical Oncology · 2025-05-28

• Data from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Supplemental Table S1 from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15